<description>&lt;div dir="auto"&gt; &lt;div dir="auto"&gt; &lt;div dir="auto"&gt; &lt;div dir="auto"&gt; &lt;div class="align-left" dir="auto"&gt;This past December, the FDA issued a Complete Response Letter to drug manufacturer Sanofi in response to Sanofi's application seeking approval for Tolebrutinib, the first in a new category of investigational disease-modifying therapies to undergo FDA review. &lt;/div&gt; &lt;div class="align-left" dir="auto"&gt; &lt;/div&gt; &lt;div class="align-left" dir="auto"&gt;A Complete Response Letter is an official letter from the FDA to a drug manufacturer stating that the agency can't approve a new medicine in its current form.&lt;span class="align-left"&gt; It'&lt;/span&gt;s not an outright "no" that kills a project; it's more like a "not yet." However, &lt;em&gt;this&lt;/em&gt; Complete Response Letter raised some issues which, at first glance, don't appear to be easily fixable.&lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;p style="text-align: center;"&gt;&lt;img src= "//assets.libsyn.com/show/105901/conte.jpg" alt="Dr. William Conte" width="380" height="398" /&gt;&lt;/p&gt; &lt;p&gt;Sanofi has pointed out that the issues raised in the Complete Response Letter were markedly different from the guidance they received from the FDA over the course of this approval process. Sanofi has also indicated that it would work with the FDA to find a path forward for Tolebrutinib.&lt;/p&gt; &lt;p&gt;Dr. William Conte, an MS Specialist and a principal investigator in the Phase 3 clinical trial for Tolebrutinib, has published an article responding to the FDA's Complete Response Letter. This week, Dr. Conte joins me to discuss the FDA's action and his response to that action. &lt;/p&gt; &lt;p style="text-align: left;"&gt;We have a &lt;em&gt;lot&lt;/em&gt; to talk about! Are you ready for RealTalk MS??!&lt;/p&gt; &lt;div align="center"&gt; &lt;hr width="25%" /&gt;&lt;/div&gt; &lt;p&gt;This Week: We're at the 2026 ACTRIMS Forum  &lt;strong&gt;:22&lt;/strong&gt;&lt;/p&gt; &lt;p&gt;Check out the official ACTRIMS Forum Insider podcast!  &lt;strong&gt;:42&lt;/strong&gt;&lt;/p&gt; &lt;p&gt;The FDA's Complete Response Letter about Tolebrutinib  &lt;strong&gt;1:09&lt;/strong&gt;&lt;/p&gt; &lt;p&gt;Dr. William Conte responds to the FDA's Complete Response Letter  &lt;strong&gt;4:09&lt;/strong&gt;&lt;/p&gt; &lt;p&gt;Share this episode  &lt;strong&gt;38:10&lt;/strong&gt;&lt;/p&gt; &lt;p&gt;Next week's episode&lt;strong&gt;  38:30&lt;/strong&gt;&lt;/p&gt; &lt;div align="center"&gt; &lt;hr width="25%" /&gt;&lt;/div&gt; &lt;p style="text-align: center;"&gt;&lt;span style= "color: #e67e23;"&gt;&lt;strong&gt;SHARE THIS EPISODE OF REALTALK MS&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt; &lt;p&gt;Just copy this link &amp; paste it into your text or email: &lt;a href="https://realtalkms.com/440" target="_blank" rel= "noopener"&gt;&lt;strong&gt;&lt;span style= "color: #e67e23;"&gt;https://realtalkms.com/440&lt;/span&gt;&lt;/strong&gt;&lt;/a&gt;&lt;/p&gt; &lt;p style="text-align: center;"&gt;&lt;span style= "color: #e67e23;"&gt;&lt;strong&gt;ADD YOUR VOICE TO THE CONVERSATION&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt; &lt;p&gt;I've always thought about the RealTalk MS podcast as a conversation. And this is &lt;em&gt;your&lt;/em&gt; opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the &lt;em&gt;RealTalk MS Listener Hotline&lt;/em&gt; and share your thoughts!&lt;/p&gt; &lt;p&gt;&lt;span style="color: #e67e23;"&gt;&lt;strong&gt;Email: &lt;a style= "color: #e67e23;" href="mailto:jon@realtalkms..com" target="_blank" rel= "noopener noreferrer"&gt;jon@realtalkms.com&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;br /&gt; &lt;span style="color: #e67e23;"&gt;&lt;strong&gt;Phone: (310) 526-2283&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt; &lt;p&gt;And don't forget to join us in the &lt;span style= "color: #e67e23;"&gt;&lt;strong&gt;&lt;a style="color: #e67e23;" href= "https://facebook.com/groups/realtalkms"&gt;RealTalk MS Facebook group&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;!&lt;/p&gt; &lt;div align="center"&gt; &lt;hr width="25%" /&gt;&lt;/div&gt; &lt;p style="text-align: center;"&gt;&lt;span style= "color: #e67e23;"&gt;&lt;strong&gt;LINKS&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt; &lt;p&gt;If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the &lt;span style= "color: #e67e23;"&gt;&lt;strong&gt;&lt;a style="color: #e67e23;" href= "https://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk" target="_blank" rel="noopener noreferrer"&gt;RealTalk MS app&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt; or at &lt;span style= "color: #e67e23;"&gt;&lt;strong&gt;&lt;a style="color: #e67e23;" title= "RealTalk MS" href="http://www.realtalkms.com/" target="_blank" rel="noopener noreferrer"&gt;www.RealTalkMS.com&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt; &lt;p&gt;&lt;strong&gt;Support Jon at WALK MS&lt;br /&gt; &lt;a href="https://realtalkms.com/walkms" target="_blank" rel= "noopener"&gt;&lt;span style= "color: #e67e23;"&gt;https://realtalkms.com/walkms&lt;/span&gt;&lt;/a&gt;&lt;br /&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p&gt;&lt;strong&gt;Find out about ABLEnow Accounts&lt;br /&gt; &lt;a href="https://ablenow.com" target="_blank" rel= "noopener"&gt;&lt;span style= "color: #e67e23;"&gt;https://ablenow.com&lt;/span&gt;&lt;/a&gt;&lt;br /&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p&gt;&lt;strong&gt;JOIN: The RealTalk MS Facebook Group&lt;/strong&gt;&lt;br /&gt; &lt;span style="color: #e67e23;"&gt;&lt;a style="color: #e67e23;" href= "https://facebook.com/groups/realtalkms" target="_blank" rel= "noopener"&gt;&lt;strong&gt;https://facebook.com/groups/realtalkms&lt;/strong&gt;&lt;/a&gt;&lt;/span&gt;&lt;/p&gt; &lt;p&gt;&lt;strong&gt;REVIEW: Give RealTalk MS a rating and review&lt;/strong&gt;&lt;br /&gt; &lt;span style="color: #e67e23;"&gt;&lt;a style="color: #e67e23;" href= "https://realtalkms.com/review" target="_blank" rel= "noopener"&gt;&lt;strong&gt;http://www.realtalkms.com/review&lt;/strong&gt;&lt;/a&gt;&lt;/span&gt;&lt;/p&gt; &lt;div align="center"&gt; &lt;hr width="25%" /&gt;&lt;/div&gt; &lt;p&gt;Follow RealTalk MS on Twitter, &lt;span style= "color: #e67e23;"&gt;&lt;strong&gt;&lt;a style="color: #e67e23;" href= "https://twitter.com/RealTalkMS_jon" target="_blank" rel= "noopener noreferrer"&gt;@RealTalkMS_jon&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;, and subscribe to our newsletter at our website, &lt;span style= "color: #e67e23;"&gt;&lt;strong&gt;&lt;a style="color: #e67e23;" href= "https://www.realtalkms.com/" target="_blank" rel= "noopener noreferrer"&gt;RealTalkMS.com&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;.&lt;/p&gt; &lt;p&gt;&lt;span style="color: #e67e23;"&gt;&lt;strong&gt;RealTalk MS Episode 440&lt;/strong&gt;&lt;/span&gt;&lt;br /&gt; &lt;span style="color: #e67e23;"&gt;&lt;strong&gt;Guests: Dr. William Conte&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt; &lt;div align="center"&gt; &lt;p&gt;&lt;span style="color: #d35400;"&gt;&lt;a style="color: #d35400;" href= "https://realtalkms.com/privacy-policy" target="_blank" rel= "noopener noreferrer"&gt;&lt;strong&gt;&lt;span style="color: #e67e23;"&gt;Privacy Policy&lt;/span&gt;&lt;/strong&gt;&lt;/a&gt;&lt;/span&gt;&lt;/p&gt; &lt;/div&gt; &lt;div id="te-floating-button-container"&gt;&lt;/div&gt; &lt;div id="te-floating-button-container"&gt;&lt;/div&gt; &lt;div id="te-floating-button-container"&gt;&lt;/div&gt; &lt;div id="te-floating-button-container"&gt;&lt;/div&gt; &lt;div id="te-floating-button-container"&gt;&lt;/div&gt;</description>

RealTalk MS

Jon Strum

Episode 440: An MS Specialist's Response to the FDA with Dr. William Conte

FEB 2, 202639 MIN
RealTalk MS

Episode 440: An MS Specialist's Response to the FDA with Dr. William Conte

FEB 2, 202639 MIN

Description

This past December, the FDA issued a Complete Response Letter to drug manufacturer Sanofi in response to Sanofi's application seeking approval for Tolebrutinib, the first in a new category of investigational disease-modifying therapies to undergo FDA review. A Complete Response Letter is an official letter from the FDA to a drug manufacturer stating that the agency can't approve a new medicine in its current form. It's not an outright "no" that kills a project; it's more like a "not yet." However, this Complete Response Letter raised some issues which, at first glance, don't appear to be easily fixable. Sanofi has pointed out that the issues raised in the Complete Response Letter were markedly different from the guidance they received from the FDA over the course of this approval process. Sanofi has also indicated that it would work with the FDA to find a path forward for Tolebrutinib. Dr. William Conte, an MS Specialist and a principal investigator in the Phase 3 clinical trial for Tolebrutinib, has published an article responding to the FDA's Complete Response Letter. This week, Dr. Conte joins me to discuss the FDA's action and his response to that action. We have a lot to talk about! Are you ready for RealTalk MS??! This Week: We're at the 2026 ACTRIMS Forum :22 Check out the official ACTRIMS Forum Insider podcast! :42 The FDA's Complete Response Letter about Tolebrutinib 1:09 Dr. William Conte responds to the FDA's Complete Response Letter 4:09 Share this episode 38:10 Next week's episode 38:30 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/440 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: [email protected] Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com Support Jon at WALK MS https://realtalkms.com/walkms Find out about ABLEnow Accounts https://ablenow.com JOIN: The RealTalk MS Facebook Group https://facebook.com/groups/realtalkms REVIEW: Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 440 Guests: Dr. William Conte Privacy Policy